Feboxa 40 Tablet contains Febuxostat 40mg, a medication primarily used to manage hyperuricemia in patients with gout. Febuxostat works by selectively inhibiting xanthine oxidase, an enzyme responsible for converting purines into uric acid, thereby reducing serum uric acid levels. This reduction helps prevent gout attacks and the formation of uric acid crystals in joints and tissues, alleviating pain and inflammation associated with gout. Feboxa 40 is typically prescribed for patients who have not responded well to other urate-lowering therapies or who are intolerant to allopurinol. It is important to take Feboxa exactly as directed by a healthcare professional, usually once daily, with or without food. Patients should inform their doctor about any history of cardiovascular disease, liver problems, or allergies before starting treatment. Common side effects may include nausea, joint pain, rash, or liver enzyme abnormalities, and any unusual symptoms should be reported promptly. Regular monitoring of uric acid levels and liver function tests is recommended during therapy to ensure safety and effectiveness. Feboxa 40 Tablet offers an effective option for long-term management of gout and hyperuricemia, improving patient quality of life by reducing the frequency and severity of gout attacks.